HEALTH CARE
<i> Times Staff and Wire Reports</i>
Medco to Pay $51.5 Million in Stock for Repligen: Medco Research Inc. said the deal will give it several new products in early stages of human testing. The Research Triangle Park, N.C.-based company said it will issue new stock to be exchanged for Repligen Corp. shares, warrants and outstanding employee options. The deal is a boost to troubled Cambridge, Mass.-based Repligen, which has been cutting staff in an effort to continue its research and development program, and it would give Medco a new product portfolio in the cardiovascular, cancer and immunology markets.
